Nyrada Completes Preclinical Studies Ahead of Stroke Therapy's Phase One Trial; Shares Climb 31%

MT Newswires Live

2024/10/16

Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.

The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.

The drug development firm anticipates the phase one trial to start later in the year, as per the filing.

The company climbed past 31% in recent Wednesday trade.

Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2475446628"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2475446628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2475446628?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-16 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475446628","market":"sh","top_or_hot":-1,"title":"Nyrada Completes Preclinical Studies Ahead of Stroke Therapy's Phase One Trial; Shares Climb 31%","media":"MT Newswires Live","content":"<html><body><p> Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.</p><p>The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.</p><p>The drug development firm anticipates the phase one trial to start later in the year, as per the filing.</p><p>The company climbed past 31% in recent Wednesday trade.</p><p>Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nyrada Completes Preclinical Studies Ahead of Stroke Therapy's Phase One Trial; Shares Climb 31%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNyrada Completes Preclinical Studies Ahead of Stroke Therapy's Phase One Trial; Shares Climb 31%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-10-16 09:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.</p><p>The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.</p><p>The drug development firm anticipates the phase one trial to start later in the year, as per the filing.</p><p>The company climbed past 31% in recent Wednesday trade.</p><p>Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475446628","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475446628","pubTimestamp":1729042460,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nyrada  completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.The drug development firm anticipates the phase one trial to start later in the year, as per the filing.The company climbed past 31% in recent Wednesday trade.Price : $0.13, Change: $+0.03, Percent Change: +31.31%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","NYR.AU":"NYRADA INC-CDI","BK4125":"广播"},"translate_title":"Nyrada在中风治疗一期试验之前完成临床前研究；股价上涨31%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"NYR.AU":0.9},"content_text":"Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.The drug development firm anticipates the phase one trial to start later in the year, as per the filing.The company climbed past 31% in recent Wednesday trade.Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}